#AbeoIt is amazing chart with invesetor or speculator
5.00$ it is good point to build Buying centers with stop loss under 3.50 $ for short term
First target for speculator 8.00 to8.70$
First Target for invesetor 21$ then 49$
0H7R trade ideas
ABEOABEO stock presents one of the best opportunities in the US market, with target prices well above $100. It is an excellent stock for investors. Currently, the stock is in a weekly upward trend and has broken through a strong supply zone from which it had bounced multiple times before. Now, it is pulling back to test this zone as a demand area, gaining momentum to push higher. The next resistance area above is the red supply zone, and if it breaks through, a new high will be set. The target for the new high ranges from $12.70 to $15-$30.
The stock is in the process of forming an inverted head-and-shoulders pattern, which will activate with a break above $9. We are waiting to buy near the range of $5.70 to $4.50,Stop loss 4$, aiming for the higher targets. After reaching $30, we will update the chart.
ABEO Long PositionABEO has a nice Long setup .
Ma cross 32/72 strategy on weekly timeframe
with 1.5 reward to risk ratio .
Entry around 4.78 cents
Stop is at 3.63 cents , which is the low of the bottom of the candle of the MA cross
target is 6.50 cents
, indicators on chart is insane oscillator from Trade oracle all Green ready to roll upside
, Ma cross, 32/72
50/50 triangle, but still below the 200 (bearish)looks like a picture-perfect triangle. Wait for confirmation and good luck.
ABEO LongAbeona Therapeutics Inc is a leading clinical-stage biopharmaceutical company. The Company develops novel gene therapies for life-threatening rare diseases. I guess the stock can surge at least to $4.94.
My trade levels:
Entry: $3.92
Take profit: $4.94
Stop loss: $3.59
Risk/reward: 3.09
Abeona Therapeutics Inc.** risky investment opportunity, $200m market capital **
Happy with the risk?
On the above 10-day chart price action has corrected a massive 95% from a high of $20 in early 2018. A number of reasons now exist to be bullish. Why?
1) Bullish divergences. Since the ‘great buy’ signal price action has continued to print lower lows while higher lows are printing with the oscillators. The monthly chart below provides a better overall illustration. Currently 7 oscillators are diverging with price action.
2) RSI resistance. After an extensive period RSI has broken resistance. This is clearly visible on both 10-day and monthly charts.
3) Volume. On the 3-month chart (bottom) volume continues to flow in as price action dips. I’ve not idea why, someone knows something I don’t. Follow the money.
Is it possible for price action to fall further? For sure.
Is it probable? Unlikely. A buy from < $2.80 is excellent.
Good luck!
WW
Monthly chart bullish divergences
3-month chart - volume
ABEO | Bullish All Year | LongAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Watch this one!Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
$ABEO Next Target PTs .60-1 and higher Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
ABEOLooking at the gap around $1.10 for a possible position.
For my educational purpose, not to be used as financial advice.
mid term +25,000% (love this one)Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.
ABEO, at support with really Nice divergence on the 4 hour. At support with really Nice divergence on the 4 hour. #NFA
ABEO for the peopleBack in let's see how it goes.
Long term higher risk hold
Not investment advice just my ideas
www.abeonatherapeutics.com
Cheers
Bullish BatABEO - H chart formed a bullish hrmonic pattern called BAT so
BUY around 2.30 to 2.10
T1 2.75
T2 3.13
SL closing below 1.90
follow-up after seeing the chart from @PlanTradePlanMMAccording to its website, it is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. Our expertise across R&D, manufacture, and discovery of novel gene and cell therapies has us uniquely positioned to bring new medicines to patients in need.
ABEO Long One swing crossed SMA50 and SMA200
trendline break and re-test
Entry 2.75
no Stop
Target 5
I am not a PRO trader. I trade option to test my trading plan with small cost.
The max Risk of each plan is less than 1% of my account.
If you like this idea, please use SIM/Demo account to try it.
ABEO W1: BEST Level to BUY/HOLD 200%+ gains(SL/TP)(STOCKS)Why get subbed to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
ABEO W1: BEST Level to BUY/HOLD 200%+ gains(SL/TP)(STOCKS)
IMPORTANT NOTE: speculative setup. do your own
due dill. use STOP LOSS. don't overleverage.
🔸 Summary and potential trade setup
::: ABEO weekly chart review and outlook
::: Biotech sector outperforming market
::: ABEO one of the best biotech stocks
::: in terms of potential upside in 2021
::: BUY dips / buy the pullback
::: noteworthy compression now
::: undergoing accumulation
::: strong bottoming pattern
::: wait for pullback/dips and BUY IT
::: recommended strategy: BUY LOW / MARKET BUY
::: TP1 +100% gains TP2 +200% gains
::: BUY/HOLD setup
::: DO NOT expect overnight gains
::: This is stock market
:::Not casino in Macau
🔸 Supply/Demand Zones
. N/A
🔸 Why should I follow your setups?
:::Check track record it's all been posted
::: MRNA 200%+ gains, NVAX 300% gains, REG 60%
::: AMD 40% gains and a lot more in 2020
::: IBB 40% gains in 2020 BUY/HOLD
